Merck known as MSD outside of the United States and Canada, today announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg mg)] in adults with HIV-1 infection…
Hansoh Pharma has granted MSD (the tradename of Merck & Co., Inc., Rahway, N.J., USA) an exclusive global license for HS-10535, its investigational oral small molecule GLP-1 receptor agonist. This collaboration represents a significant step in advancing therapies for cardiometabolic…
Eli Lilly and Company announced today that China’s National Medical Products Administration (NMPA) has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Lilly’s Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease. This includes individuals…
Merck known as MSD outside of the United States and Canada, has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab was being evaluated in combination with pembrolizumab (KEYTRUDA®) in the…
Takeda is hosting an investor R&D Day today, starting at 8:30 a.m. JST in Tokyo. The event will highlight the company’s late-stage pipeline, focusing on its transformative potential for patients and the market opportunities these therapies present. Christophe Weber, Takeda’s…
Updated results from the OlympiA Phase III trial revealed that AstraZeneca and MSD’s Lynparza (olaparib) continues to show significant, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) at six years for patients…
Celltrion has announced that Health Canada has approved Omlyclo™, the first and only biosimilar referencing Xolair® (omalizumab) in Canada. Omlyclo™ is now authorized for the treatment of adults and adolescents with chronic idiopathic urticaria (CIU), also known as chronic spontaneous…
On November 29, the Group of Friends of Traditional Medicine convened in Geneva to explore opportunities for joint action in 2025, fostering collaboration and coordination among WHO Member States. Ambassadors and health representatives from nearly 30 countries gathered for a…
Roche presented new and updated findings from its pioneering CD20xCD3 T-cell-engaging bispecific antibody program at the 66th American Society of Hematology (ASH) Annual Meeting, held from December 7-10, 2024. With over 20 abstracts accepted, the data emphasize the potential of…
Legend Biotech Corporation a global leader in cell therapy, recently unveiled groundbreaking results from the Phase 3 CARTITUDE-4 clinical trial, further cementing the efficacy of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in treating relapsed or lenalidomide-refractory multiple myeloma. These results, presented at…
Kite, a Gilead Company presented new findings from three analyses on Yescarta® (axicabtagene ciloleucel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) at the 66th Annual Meeting & Exposition of the American Society of Hematology (ASH). These findings demonstrate…
Blueprint Medicines Corporation presented compelling new data at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the long-term benefits of AYVAKIT® (avapritinib) in treating systemic mastocytosis (SM). These findings reflect the company’s commitment to transforming patient care through…